

Nivolumab CheckMate 057

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Improved QoL

Serious and disabling adverse effects



Less serious adverse events observed


Other adjustments



Nivolumab CheckMate 057

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: Locally advanced or metastatic squamous NSCLC after prior ChT
Experimental Arm: Nivolumab
Control Arm: Docetaxel

